CD274 and neoplasm: In a recent study published in Nature, Grippin and colleagues showed that SARS-CoV-2 mRNA vaccines can transiently reset the tumor–immune interface, converting immunologically “cold” tumors into those that respond to PD-1/PD-L1 blockade.